Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Nivolumab Granted Priority Review by the FDA for Nonsquamous NSCLC
Nivolumab (Opdivo) was given a priority review designation by the FDA for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC).
A new study suggests that the presence of persistent genetic mutations, 30 days after induction chemotherapy, predicted relapse and survival in patients with acute myeloid leukemia (AML), as well as intermediate-risk patients.
Rolapitant (Varubi) was recently approved by the FDA for use in combination with other antiemetic agents, in order to prevent delayed CINV from initial and repeat chemotherapy regiments, including highly emetogenic chemotherapy.
Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses HER2-positive breast cancer advancements.
View More >


HCC Monitor
HCC Monitor
Liver cancer news and updates
Engineered T Cells for Leukemia: A Review of Current Approaches and Applications
This review addresses the basics of CAR T-cell design and reviews data from published clinical studies in leukemia. It also contains commentary on the prospects of this promising new therapeutic strategy.
Hypertension Risk Among Cancer Patients Treated With Sunitinib: A Meta-analysis and Systematic Review
Sunitinib treatment is associated with a significantly increased risk of all-grade and high-grade hypertension.
Evolving Paradigms: Gynecologic Cancer
In the past decade, there has been a rapid increase in the understanding of how various cancers develop and progress, which has led to the advance of novel and more targeted strategies for the prevention, diagnosis, and treatment of many malignancies.
$vacMongoViewPlus$ $vAR$